Literature DB >> 29109754

Understanding the impact of hypoglycemia on the cardiovascular system.

Ian Charles Davis1, Ida Ahmadizadeh1, Jacqueline Randell2, Lisa Younk1, Stephen N Davis3.   

Abstract

INTRODUCTION: Hypoglycemia occurs commonly in insulin requiring individuals with either Type 1 or Type 2 Diabetes. AREAS COVERED: This article will review recent information on the pro-inflammatory and pro-atherothrombotic effects of hypoglycemia. Additionally, effects of hypoglycemia on arrhythmogenic potential and arterial endothelial dysfunction will be discussed. Effects of hypoglycemia on cardiovascular morbidity and mortality from large clinical studies in Type 1 and Type 2 DM will also be reviewed. EXPERT COMMENTARY: The relative and absolute risk of severe hypoglycemia leading to death and serious adverse events in both cardiovascular and other organ systems has been highlighted following the publication of recent large clinical trials focused on glucose control and outcomes. It would be helpful if future studies could develop broader end points to include minor and moderate hypoglycemia as well as more robust methods for capturing hypoglycemia contemporaneously with adverse events. In addition, perhaps consideration of including hypoglycemia as a primary outcome, may help identify the possible cause and effect of hypoglycemia on cardiovascular morbidity and mortality.

Entities:  

Keywords:  Atherothrombosis; Diabetes; Dysrhythmia; Fibrinolytic Balance; Hypoglycemia; Inflammation

Year:  2017        PMID: 29109754      PMCID: PMC5669378          DOI: 10.1080/17446651.2017.1275960

Source DB:  PubMed          Journal:  Expert Rev Endocrinol Metab        ISSN: 1744-6651


  82 in total

1.  Recurrent hypoglycemia: boosting the brain's metabolic flexibility.

Authors:  Marina Litvin; Amy L Clark; Simon J Fisher
Journal:  J Clin Invest       Date:  2013-04-01       Impact factor: 14.808

2.  A Link Between Hypoglycemia and Progression of Atherosclerosis in the Veterans Affairs Diabetes Trial (VADT).

Authors:  Aramesh Saremi; Gideon D Bahn; Peter D Reaven
Journal:  Diabetes Care       Date:  2016-01-19       Impact factor: 19.112

Review 3.  Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis.

Authors:  Atsushi Goto; Onyebuchi A Arah; Maki Goto; Yasuo Terauchi; Mitsuhiko Noda
Journal:  BMJ       Date:  2013-07-29

4.  Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study.

Authors:  Kamlesh Khunti; Melanie Davies; Azeem Majeed; Brian Larsen Thorsted; Michael Lyng Wolden; Sanjoy K Paul
Journal:  Diabetes Care       Date:  2014-12-09       Impact factor: 19.112

5.  Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration.

Authors: 
Journal:  Diabetologia       Date:  2007-04-06       Impact factor: 10.122

6.  QT dispersion and sudden unexpected death in chronic heart failure.

Authors:  C S Barr; A Naas; M Freeman; C C Lang; A D Struthers
Journal:  Lancet       Date:  1994-02-05       Impact factor: 79.321

7.  QTc interval prolongation is independently associated with severe hypoglycemic attacks in type 1 diabetes from the EURODIAB IDDM complications study.

Authors:  Gabriella Gruden; Sara Giunti; Federica Barutta; Nish Chaturvedi; Daniel R Witte; Marinella Tricarico; John H Fuller; Paolo Cavallo Perin; Graziella Bruno
Journal:  Diabetes Care       Date:  2011-11-28       Impact factor: 19.112

8.  Effects of Acute and Antecedent Hypoglycemia on Endothelial Function and Markers of Atherothrombotic Balance in Healthy Humans.

Authors:  Nino G Joy; Donna B Tate; Lisa M Younk; Stephen N Davis
Journal:  Diabetes       Date:  2015-02-18       Impact factor: 9.461

9.  Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study.

Authors:  K Khunti; S Alsifri; R Aronson; M Cigrovski Berković; C Enters-Weijnen; T Forsén; G Galstyan; P Geelhoed-Duijvestijn; M Goldfracht; H Gydesen; R Kapur; N Lalic; B Ludvik; E Moberg; U Pedersen-Bjergaard; A Ramachandran
Journal:  Diabetes Obes Metab       Date:  2016-06-20       Impact factor: 6.577

10.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse
Journal:  N Engl J Med       Date:  2016-06-13       Impact factor: 176.079

View more
  14 in total

1.  Low HbA1c levels and all-cause or cardiovascular mortality among people without diabetes: the US National Health and Nutrition Examination Survey 1999-2015.

Authors:  Kosuke Inoue; Roch Nianogo; Donatello Telesca; Atsushi Goto; Vahe Khachadourian; Yusuke Tsugawa; Takehiro Sugiyama; Elizabeth Rose Mayeda; Beate Ritz
Journal:  Int J Epidemiol       Date:  2021-08-30       Impact factor: 7.196

2.  Myocardial Protective Effects of Nicorandil on Rats with Type 2 Diabetic Cardiomyopathy.

Authors:  Meng Zhang; Huizhen Zhang; Chun Liu; Xuehui Li; Mingying Ling; Zhihao Wang; Yanqiu Xing
Journal:  Med Sci Monit Basic Res       Date:  2018-09-28

3.  Severe hypoglycemia and the risk of cardiovascular disease and mortality in type 2 diabetes: a nationwide population-based cohort study.

Authors:  Jae-Seung Yun; Yong-Moon Park; Kyungdo Han; Seon-Ah Cha; Yu-Bae Ahn; Seung-Hyun Ko
Journal:  Cardiovasc Diabetol       Date:  2019-08-14       Impact factor: 9.951

4.  Hypoglycaemia leads to a delayed increase in platelet and coagulation activation markers in people with type 2 diabetes treated with metformin only: Results from a stepwise hypoglycaemic clamp study.

Authors:  Felix Aberer; Peter N Pferschy; Norbert J Tripolt; Caren Sourij; Anna M Obermayer; Florian Prüller; Eva Novak; Philipp Reitbauer; Harald Kojzar; Barbara Prietl; Selina Kofler; Martina Brunner; Eva Svehlikova; Tatjana Stojakovic; Hubert Scharnagl; Abderrahim Oulhaj; Faisal Aziz; Regina Riedl; Harald Sourij
Journal:  Diabetes Obes Metab       Date:  2019-11-03       Impact factor: 6.577

Review 5.  Diabetic Cardiomyopathy: Impact of Biological Sex on Disease Development and Molecular Signatures.

Authors:  Ryan Toedebusch; Anthony Belenchia; Lakshmi Pulakat
Journal:  Front Physiol       Date:  2018-05-03       Impact factor: 4.566

6.  Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitus.

Authors:  Victor Sokolov; Tatiana Yakovleva; Shinya Ueda; Joanna Parkinson; David W Boulton; Robert C Penland; Weifeng Tang
Journal:  Diabetes Obes Metab       Date:  2018-12-16       Impact factor: 6.577

Review 7.  Epidemiology, Quality of Life, and Costs Associated with Hypoglycemia in Patients with Diabetes in Spain: A Systematic Literature Review.

Authors:  Mercedes Núñez; Silvia Díaz; Tatiana Dilla; Jesús Reviriego; Antonio Pérez
Journal:  Diabetes Ther       Date:  2019-01-19       Impact factor: 2.945

Review 8.  Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis.

Authors:  Majid Mobasseri; Masoud Shirmohammadi; Tarlan Amiri; Nafiseh Vahed; Hossein Hosseini Fard; Morteza Ghojazadeh
Journal:  Health Promot Perspect       Date:  2020-03-30

9.  Physiological monitoring of the complex multimorbid heart failure patient - diabetes and monitoring glucose control.

Authors:  Petar M Seferović; Pardeep S Jhund
Journal:  Eur Heart J Suppl       Date:  2019-12-31       Impact factor: 1.803

10.  Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial.

Authors:  David Fitchett; Silvio E Inzucchi; Christoph Wanner; Michaela Mattheus; Jyothis T George; Ola Vedin; Bernard Zinman; Odd Erik Johansen
Journal:  Eur Heart J       Date:  2020-01-07       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.